01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamins for use in the manufacture of food supplements;
chemical additives for vitamins; chemical supplements for
use in the manufacture of vitamins; vitamins for the
manufacture of food supplements; vitamins for use in the
manufacture of pharmaceuticals. Food supplements; nutritional supplements; vitamin
supplements; dietary supplements; vitamin B preparations;
vitamin preparations; dietary supplements consisting of
vitamins; vitamins and vitamin preparations; vitamin
preparations; fertility enhancement preparations.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamins used as active ingredients in the manufacture of
pharmaceutical preparations, food preparations, food
supplements. Vitamins; vitamin supplements; dietetic substances composed
of dietetic vitamins for medical and pharmaceutical use;
food supplements; nutritional and dietetic supplements;
bacteria and bacterial preparations for pharmaceutical or
medical use; preparations of probiotics or other nutrients
for human consumption; probiotic composition for human food;
culture of micro-organisms with a probiotic effect on the
human organism, for medical use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Vitamins for use in the manufacture of food supplements; chemical additives for vitamins; chemical supplements for use in the manufacture of vitamins; vitamins for the manufacture of food supplements; vitamins for use in the manufacture of pharmaceuticals.
(2) Food supplements containing folates for health and general well-being; nutritional supplements containing folates for health and general well-being; vitamin supplements; dietary supplements containing folates for health and general well-being; vitamin B preparations; vitamin preparations; dietary supplements consisting of vitamins; vitamins and vitamin preparations; vitamin preparations; fertility enhancement preparations for human use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements
(2) Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use namely nutritional yeast and probiotic; food supplements for the overall health and well-being of the body; food supplements based on micro-organisms namely nutritional actives, nutritional yeasts and probiotics for general health and well-being; bacteria and bacterial preparations for pharmaceutical and medical use for the overall health and well-being of the body; preparations of probiotics for human consumption for the overall health and well-being of the body; probiotic composition for human food for medical use; culture of micro-organisms with a probiotic effect on the human organism, for medical use namely yeast.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements, all of the foregoing containing menaquinone-7 in whole or significant part Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; preparations of probiotics for human consumption; nutrients for human consumption being dietary and nutritional supplements; probiotic composition for human food being dietary and nutritional supplements; culture of micro-organisms with a probiotic effect on the human organism, for medical use; all of the foregoing containing menaquinone-7 in whole or significant part
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamins used as active ingredients in the manufacture of
pharmaceutical preparations, food preparations, food
supplements. Vitamins; vitamin supplements; dietetic substances composed
of dietetic vitamins for medical and pharmaceutical use;
food supplements; nutritional and dietetic supplements;
bacteria and bacterial preparations for pharmaceutical or
medical use; preparations of probiotics or other nutrients
for human consumption; probiotic composition for human food;
culture of micro-organisms with a probiotic effect on the
human organism, for medical use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements.
(2) Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use namely nutritional yeast and probiotic; food supplements for the overall health and well-being of the body; food suppléments based on micro-organisms namely nutritional actives, nutritional yeasts and probiotics for general health and well-being; bacteria and bacterial preparations for pharmaceutical and medical use for the overall health and well-being of the body; preparations of probiotics for human consumption for the overall health and well-being of the body; probiotic composition for human food for medical use; culture of micro-organisms with a probiotic effect on the human organism, for medical use namely yeast.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations and food supplements, all of the foregoing containing menaquinone-7 in whole or significant part Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; preparations of probiotics for human consumption; nutrients for human consumption being dietary and nutritional supplements; probiotic composition for human food being dietary and nutritional supplements; culture of micro-organisms with a probiotic effect on the human organism, for medical use; all of the foregoing containing menaquinone-7 in whole or significant part
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements. Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; bacteria and bacterial preparations for pharmaceutical or medical use; preparations of probiotics or other nutrients for human consumption; probiotic composition for human food; culture of micro-organisms with a probiotic effect on the human organism, for medical use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamins used as active ingredients in the manufacture of pharmaceutical preparations, food preparations, food supplements. Vitamins; vitamin supplements; dietetic substances composed of dietetic vitamins for medical and pharmaceutical use; food supplements; nutritional and dietetic supplements; bacteria and bacterial preparations for pharmaceutical or medical use; preparations of probiotics or other nutrients for human consumption; probiotic composition for human food; culture of micro-organisms with a probiotic effect on the human organism, for medical use.
The invention relates to reduced glutathione in a highly water-soluble solid form, the process for the preparation thereof, and pharmaceutical, nutraceutical or veterinary formulations containing it.
The invention relates to the salt of (SS)-adenosyl methionine with myo-inositol 1,2,3,4,5,6 hexakisphosphate, and pharmaceutical, nutraceutical or veterinary formulations containing it.
A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
18.
PROCESS FOR THE PURIFICATION OF LIPOPOLYPEPTIDE ANTIBIOTICS
Disclosed is a process for the purification of lipopolypeptide antibiotics from culture broths which comprises: a) removal of the mycelium from the broth; b) anion-exchange chromatography of the solution resulting from stage a), eluting with di- or trivalent ions; c) optional concentration of the purified fraction resulting from stage b); d) hydrophobic interaction chromatography of the fraction resulting from stage b) or c), eluting with C1-C4 alcohols; e) cation-exchange chromatography of the desired lipopolypeptide-enriched fraction resulting from stage d), eluting at a pH equal to or greater than the isoelectric point of the lipopolypeptide; f) dialysis, concentration and freeze-drying or spray-drying of the purified lipopolypeptide.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.
C07C 37/07 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation with simultaneous reduction of C=O group in that ring
C07C 37/84 - SeparationPurificationStabilisationUse of additives by physical treatment by crystallisation
C07C 39/225 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a condensed ring system
C12P 7/22 - Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical compositions; pharmaceutical products;
pharmaceutical preparations for veterinary use;
neutraceutical preparations for veterinary and human use;
vitamin supplements; probiotic supplements; homeopathic
supplements; nutritional supplements for medical use;
dietetic supplements for medical use; nutritional
supplements for medical use; mineral supplements for medical
use; feed supplements for veterinary use; dietary
supplemental drinks; food supplements for non-medical
purposes; nutraceuticals for use as a dietary supplement;
vitamin preparations in the nature of food supplements;
dietetic substances for medical use; dietetic food and
preparations for medical use; dietetic substances adapted
for veterinary use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical compositions namely pharmaceutical compositions for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; pharmaceutical products namely pharmaceutical preparations for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; pharmaceutical preparations for veterinary use for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; nutraceutical preparations for veterinary and human use namely stabilized bulk powder in the form of phytate for use in the manufacture of nutraceuticals; vitamin supplements; probiotic supplements; homeopathic supplements in the form of liquid and caplets, for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; nutritional supplements for medical use namely supplements for the promotion of healthy liver function, for the treatment and prevention of joints pain, mood disorders and for the promotion of the induction of ovulation; dietetic supplements for medical use namely vitamins; mineral supplements for medical use; feed supplements for veterinary use namely animal feed supplements for veterinary purposes; dietary supplemental drinks namely liquid vitamin supplements; food supplements for non-medical purposes namely bee pollen for use as a dietary food supplement; nutraceuticals for use as a dietary supplement namely dietary supplements for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation; vitamin preparations in the nature of food supplements namely vitamin and mineral food supplements; dietetic food and preparations for medical use namely dietetic substances consisting of vitamins, minerals, amino acids and trace elements; dietetic substances adapted for veterinary use namely stabilized bulk powder in the form of phytate for use in the manufacture of nutraceuticals for the treatment and prevention of joints pain, for the promotion of healthy liver function, mood disorders and for the promotion of the induction of ovulation
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamin supplements; Probiotic supplements; Homeopathic supplements; Nutritional supplements for medical use; Dietetic supplements for medical use, namely, dietary supplements; Mineral supplements for medical use; Animal feed supplements for veterinary use; Dietary supplemental drinks; Food supplements for non-medical purposes; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Dietetic food and preparations being vitamins, capsules and tablets adapted for medical use; Dietetic substances being foods, croquettes and chewable tablets adapted for veterinary use; all of the foregoing goods containing S- Adenosyl methionine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical compositions; Pharmaceuticals; Pharmaceutical preparations for veterinary use; Nutraceutical preparations for human and veterinary use; Vitamin supplements; Probiotic supplements; Homeopathic supplements; Nutritional supplement for medical use; Nutritional supplements; Nutritional supplements; Mineral supplements for medical purposes; Nutritional supplements for veterinary use; Dietary supplemental drinks; Food supplements for non-medical purposes; Nutraceuticals for use as a dietary supplement; Vitamin preparations in the nature of food supplements; Dietetic substances adapted for medical use; Dietetic foodstuffs and substances adapted for medical use; Dietetic substances adapted for veterinary use.
The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.
C07C 37/07 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation with simultaneous reduction of C=O group in that ring
C07C 37/84 - SeparationPurificationStabilisationUse of additives by physical treatment by crystallisation
C07C 39/225 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a condensed ring system
C12P 7/22 - Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
36.
Crystalline forms of s-acetyl glutathione, their preparations and uses in pharmaceutical and nutraceutical formulations
Disclosed are two novel crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallization of SAG from mixtures of water-acetone, water-ethanol or water acetone under controlled conditions. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.
E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them.
This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof.
This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 9/46 - Pills, lozenges or tablets effervescent
The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: c) a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and d) an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: c) a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and d) an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
51.
CRYSTALLINE FORMS OF S-ACETYL GLUTATHIONE, THEIR PREPARATIONS AND USES IN PHARMACEUTICAL AND NUTRACEUTICAL FORMULATIONS
Disclosed are two crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallisation of SAG from mixtures of water-acetone, water-ethanol or water-methanol, preferably acetone, under controlled conditions. The crystalline forms are characterised by X-ray powerder diffrraction, IR spectrum and DSC. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.
Disclosed are two crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallisation of SAG from mixtures of water-acetone, water-ethanol or water-methanol, preferably acetone, under controlled conditions. The crystalline forms are characterised by X-ray powerder diffrraction, IR spectrum and DSC. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic food and
substances adapted for medical or veterinary use, food for
babies; dietary supplements for humans and animals;
plasters, materials for dressings; material for stopping
teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides.
S-adenosyl methionine, and the salts and complexes thereof, in the form of a spray-dried sterile powder which has a pharmacologically active enantiomer content exceeding 70% and a water residue below 2.5% by weight.
A61K 9/19 - Particulate form, e.g. powders lyophilised
C07C 281/18 - Compounds containing any of the groups e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
A61K 9/00 - Medicinal preparations characterised by special physical form
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Food and dietetic substances adapted for medical or veterinary use, food for babies; Dietary supplements for humans and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides.
The present invention describes combinations comprising chondroitin sulphate (CS), one or more enzymes or enzymatic mixtures possessing proteolytic activity, and sulphydryl compounds, for the treatment and prevention of osteoarthritis and correlated acute and chronic inflammatory processes, or as nutraceutical compositions for the maintenance of musculoskeletal well-being in humans and animals. The characteristic of said combinations is that they increase the intestinal absorption of CS when administered orally. The effect of said combinations is exerted on a wide range of molecular weights of CS, including CS samples with very low molecular weights which already possess greater bioavailability than samples with a higher molecular weight. The effect is exerted on CS samples of any origin.
The present invention describes combinations comprising chondroitin sulphate (CS), one or more enzymes or enzymatic mixtures possessing proteolytic activity, and sulphydryl compounds, for the treatment and prevention of osteoarthritis and correlated acute and chronic inflammatory processes, or as nutraceutical compositions for the maintenance of musculoskeletal well-being in humans and animals. The characteristic of said combinations is that they increase the intestinal absorption of CS when administered orally. The effect of said combinations is exerted on a wide range of molecular weights of CS, including CS samples with very low molecular weights which already possess greater bioavailability than samples with a higher molecular weight. The effect is exerted on CS samples of any origin.
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible for addition of fructose residues to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
Disclosed is a low-molecular-weight (1000-5000 daltons) chondroitin sulphate (CS) produced by chemical sulphation and subsequent depolymerisation of a non-sulphated chondroitin backbone obtained with biotechnology techniques. The CS described is substantially monosulphated, mainly at the 6-position, with very little sulphation at the 4-position, and with a mono/disulphated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin 6-sulphate (C6S) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Food supplements, herbal supplements, botanicals, botanical extracts, and nutraceuticals for medical or veterinary use for improving metabolism, mood and brain functions, liver health and joint health, and for general health and well-being, food for babies; dietary supplements for humans and animals for improving metabolism, mood and brain functions, liver health and joint health, and for general health and well-being.
74.
Composition comprising shellac and/or a salt thereof and sodium starch glycolate
The object of the present invention is a composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
The present invention concerns a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark¬ like chondroitin sulphate, showing a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates; the invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and charge density; its in vitro biological and anti-inflammatory effectiveness, comparable to the ones of natural products make this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals.
The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4, or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4, or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
The object of the present invention is a composition shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.
The object of the present invention is a composition shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible of fructose residues addition to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12P 15/00 - Preparation of compounds containing at least three condensed carbocyclic rings
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible for addition of fructose residues to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible of fructose residues addition to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin.
The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use, food for babies; plasters,
materials for dressings; material for stopping teeth, dental
wax; disinfectants; preparations for destroying vermin;
fungicides, herbicides.
The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
93.
USE OF S-ADENOSYLMETHIONINE (SAM) AND SUPEROXIDE DISMUTASE (SOD) FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
The use of S-adenosylmethionine (SAM) in combination with superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
95.
PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID
The invention relates to a process for the diastereoisomeric resolution of 5-methyltetrahydrofolic acid; it discloses also a crystalline amine salt of 5-methyltetrahydrofolic acid and is further directed to a process for the transformation of the single diastereoisomers of the 5-methyltetrahydrofolic amine salts obtained by the process of the invention into the corresponding free acid or into an alkaline earth metal salt. The invention provides a simple, economically advantageous and efficient process and allows to obtain stable and pure (6R) and ( 6S) -diastereoisomers of 5-methyltetrahydrofolic acid in a good yield and diastereoisomeric purity.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.
The invention relates to pharmaceutical and nutraceutical compositions containing as the active ingredient a menaquinol of formula (I) wherein n is as defined in the description, for the prevention of cardiovascular diseases and bone metabolism disorders.
